Litmus email source
Copy source
<!DOCTYPE html><html lang="en" style="background-color:#ffffff;margin:0;padding:0"><head> <title>Scholar Rock</title> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml><o:OfficeDocumentSettings><o:AllowPNG/><o:PixelsPerInch>96</o:PixelsPerInch></o:OfficeDocumentSettings></xml> <![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table{border-collapse:collapse;border-spacing:0;mso-line-height-rule:exactly;mso-margin-bottom-alt:0;mso-margin-top-alt:0;mso-table-lspace:0pt;mso-table-rspace:0pt;} </style> <![endif]--> <!--[if gte mso 9]> <style>li{margin-left:12px !important;mso-special-format:bullet;} </style> <![endif]--> <!--[if gte mso 9]> <style>sup,sub{font-size:100% !important;} </style> <![endif]--> <style>#outlook a{padding:0;}.ReadMsgBody{width:100%;}body,table,td,a{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;}table,td{mso-table-lspace:0pt;mso-table-rspace:0pt;}img{-ms-interpolation-mode:bicubic;}body{margin:0;padding:0;}img{border:0;height:auto;line-height:100%;outline:none;text-decoration:none;}table{border-collapse:collapse!important;border-spacing:0!important;}html,body{margin:0 auto!important;padding:0!important;height:100%!important;width:100%!important;}p{margin:0 !important;padding:0!important;}u+.body .listGmail{margin-left:20px!important;} @media (max-width:640px){u+.body .listGmail{margin-left:14px!important;}u+.body .listGmail li{padding-left:6px!important;} }.nolink a{color:inherit!important;text-decoration:none!important;font-size:inherit!important;font-family:inherit!important;font-weight:inherit!important;line-height:inherit!important;} </style> </head> <body width="100%" style="margin:0;color:#000000;font-family:Arial,Helvetica,Verdana,sans-serif;font-size:16px;line-height:22px;mso-line-height-rule:exactly;-webkit-font-smoothing:antialiased;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;background-color:#ffffff;padding:0;height:100%;width:100%"><center style="width:100%"><div style="display:none;width:0;height:0;max-height:0;line-height:0;mso-hide:all;overflow:hidden;visibility:hidden;padding:0;margin:0;font-size:1px;color:#ffffff; line-height:1px;opacity:0"> Discover what this could mean for your patients ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ </div> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#12A166;padding-left:20px;padding-right:20px;padding-top:6px;padding-bottom:6px"><div style="box-sizing:border-box;text-align:center;display:block;margin:0;margin-bottom:0;mso-line-height-rule:exactly;font-family:Arial,Helvetica, sans-serif;font-size:14px;line-height:18px;font-weight:700;color:#00205B"> <a href="https://www.isembyldhcp.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isi_header_0297#isi" target="_blank" style="color:#00205B;text-decoration:underline">Important Safety Information</a> | <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_header_0297" target="_blank" style="color:#00205B;text-decoration:underline">Prescribing Information</a></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-bottom:8px;padding-top:12px"><div style="box-sizing:border-box;text-align:center;display:block;margin:0 auto;margin-bottom:12px;"> <a href="https://www.isembyldhcp.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isembyld_logo_header_0297" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-now-approved-email/logo-isembyld.png" width="200" height="68" border="0" alt="ISEMBYLD brand logo" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic"></a></div><div style="box-sizing:border-box;display:block;margin:0; margin-bottom:24px;mso-line-height-rule:exactly;text-align:center;font-family:'Arial Black',Arial,Helvetica,sans-serif;font-size:22px;line-height:26px;font-weight:900;color:#00205B">Now Approved: <i>The First and Only <span style="white-space:nowrap;">Muscle-Targeted</span> Treatment for SMA<sup style="font-size:70%;line-height:1">1</sup></i></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:12px; line-height:18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Hello/Dear/Hi/Good morning/Good afternoon/Good evening/Greetings] [Dr/Doctor/Miss/Mr/Mrs/Ms] [Type in recipient’s name]<span style="color:#000000">,</span></p></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left; font-family:Arial,Helvetica,sans-serif;font-size:12px;line-height:18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [It’s nice to meet you over email. I want to share some information on ISEMBYLD, a new treatment option for adult and pediatric patients with SMA who are 2 years of age and older and are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment./I am looking forward to our upcoming meeting. In preparation, I want to share some information on ISEMBYLD, a new treatment option for adult and pediatric patients with SMA who are 2 years of age and older and are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment. We can review it together in more detail when we meet./It was great to connect with you recently. Based on our conversation, I thought you would be interested in this information on ISEMBYLD, a new treatment option for adult and pediatric patients with SMA who are 2 years of age and older and are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment./I hope you have been well. I wanted to follow up with the information that we discussed about ISEMBYLD, a new treatment option for adult and pediatric patients with SMA who are 2 years of age and older and are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment./I’m reaching out to share some information about a new treatment option for adult and pediatric patients with SMA who are 2 years of age and older and are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment.] </p></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#12A166;padding:20px;padding-left:24px;padding-right:24px;padding-top:30px;padding-bottom:30px"><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:16px;mso-line-height-rule: exactly;text-align:left;font-size:14px;line-height:18px;font-weight:700;color:#00205B"> Progressive muscle wasting is a clinical hallmark of SMA,<sup style="font-size:70%;line-height:1">2</sup> and long-term clinical data demonstrate that after initial motor function improvement, many patients with SMA who are on survival motor neuron 2 (<i>SMN2</i>)-targeted treatment experience a period of stabilization, then eventual decline to or below baseline.<sup style="font-size:70%;line-height: 1">3,4</sup></div> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" style="border:solid 2px #00205B;border-collapse:collapse;padding:0;margin:0;padding-left:20px;padding-right:20px;padding-top:12px;padding-bottom:12px;background:#ffffff;"><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-size:14px;line-height:18px;font-weight:700;color:#00205B"> ISEMBYLD is indicated for the treatment of SMA in adults and pediatric patients 2 years of age and older who are currently receiving an <span style="white-space:nowrap;">SMN2‑targeted</span> treatment.<sup style="font-size:70%;line-height:1">1</sup></div> </td></tr></tbody></table> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-bottom:8px;padding-top:20px"><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:16px;mso-line-height-rule: exactly;text-align:left;font-size:16px;line-height:22px;font-weight:700;color:#00205B"> ISEMBYLD demonstrated clinically meaningful gains in motor function<sup style="font-size:70%;line-height:1">1</sup></div><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:18px;mso-line-height-rule:exactly;text-align:left;font-size:14px;line-height:18px;font-weight:700;color:#00205B"> SAPPHIRE was a pivotal, phase 3, randomized, double-blind, placebo-controlled, multicenter study in patients with SMA aged 2-21 years (N=188).<sup style="font-size:70%;line-height:1">1</sup></div><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:18px;mso-line-height-rule:exactly;text-align:left;font-size:14px;line-height:18px;font-weight:400;color:#00205B"> The main efficacy population consisted of 156 patients aged 2-12 years; 53 were randomized to receive ISEMBYLD 10 mg/kg (the recommended dose) via intravenous infusion once every 4 weeks for approximately 52 weeks, and 50 were randomized to receive placebo. All patients were receiving an approved <i>SMN2</i>-targeted treatment (nusinersen or risdiplam).<sup style="font-size:70%;line-height:1">1</sup></div> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" style="padding:0;margin:0;padding-left:35px;padding-right:35px;padding-top:24px;padding-bottom:24px;background:#12A166;"><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:16px;mso-line-height-rule:exactly;text-align:left;font-size:14px;line-height:18px;font-weight:700;color:#00205B"> Primary endpoint was mean change from baseline at 52 weeks in the Hammersmith Functional Motor Scale—Expanded (HFMSE), the most widely studied motor function scale in SMA.<sup style="font-size:70%;line-height:1">1,5</sup></div> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td width="8" style="width:8px;"> </td><td width="12" style="width:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#00205B;font-size:14px;line-height:18px;font-weight:bold;" align="left" valign="top">• </td><td style="font-family:Arial,Helvetica,Verdana,sans-serif;color:#00205B;font-size:14px;line-height:18px;font-weight:bold;" align="left" valign="top">ISEMBYLD (10 mg/kg) with an <i>SMN2</i>-targeted treatment (n=53) showed a clinically meaningful 2.2-point improvement in HFMSE score over <i>SMN2</i>-targeted treatment alone (n=50) at 1 year (nominal P value=0.0121) in patients aged 2-12 years. Treatment effect was consistent across predefined subgroups including adults and adolescents.* </td></tr></tbody></table> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td style="font-family:Arial,Helvetica,Verdana,sans-serif;color:#00205B;font-size:10px;line-height:12px;font-weight:normal;padding-top:20px;" align="left" valign="top">*The adults and adolescent subgroup was defined as individuals in the study aged 13-21 years. </td></tr></tbody></table> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0" align="center" style="margin:0 auto;"><tr><td width="600"> <![endif]--> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="max-width:600px;box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;vertical-align:top;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-top:16px;padding-bottom:16px" valign="top"><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family: Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> INDICATION </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:20px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> ISEMBYLD (apitegromab-mstn) is indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 <span style="white-space:nowrap;">(SMN2)‑targeted</span> treatment. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> IMPORTANT SAFETY INFORMATION </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold; font-size:14px;line-height:16px;color:#00205B"> WARNINGS AND PRECAUTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Fractures </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color: #00205B"> ISEMBYLD may increase the risk of fractures, including serious fractures. Use with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> ADVERSE REACTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> The most common adverse reactions (incidence ≥20% of patients treated with ISEMBYLD and more frequent than placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. </div><div style="box-sizing: border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> USE IN SPECIFIC POPULATIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Pregnancy and Lactation </div><div style="box-sizing:border-box;text-align:left; display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may cause fetal harm. There are no adequate data on the developmental risk associated with the use of ISEMBYLD in pregnant women. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px; line-height:16px;color:#00205B"> There are no data on the presence of ISEMBYLD in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ISEMBYLD, and any potential adverse effects on the breastfed infant. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica, Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Females and Males of Reproductive Potential </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may affect male and/or female reproductive function. </div><div style="box-sizing:border-box;text-align:left;display:block; margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Please see full <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_body_0297" target="_blank" style="text-decoration:underline;color:#00205B">Prescribing Information</a>. </div> </td></tr></tbody></table> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-top:0"><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:12px;line-height: 18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB">[I’d like to discuss further the recent FDA approval of ISEMBYLD, the first muscle-targeted treatment in SMA. Please let me know the date, time, and location that is best for you, and I will follow up with a meeting invitation./I look forward to meeting with you soon–and please reach out with any questions in the meantime./Let’s talk further about how ISEMBYLD could benefit children and adults with SMA. Please let me know the best date, time, and location for you, and I will follow up with a meeting invitation.]</p></div> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" style="padding-bottom:8px"> <!--[if (gte mso 9)|(IE)]> <table border="0" cellpadding="0" cellspacing="0" width="280"><tr><td width="160" valign="top" align="left"> <![endif]--><div style="display:inline-block;width:100%;max-width:160px;vertical-align:top;"> <table border="0" cellpadding="0" cellspacing="0" width="150" role="none"><tbody><tr><td valign="middle" align="center" width="150" style="width:150px;border:2px solid #00205b;height:32px;background-color:#12A166;text-align:center;color:#00205B"> <a href="https://isembyldhcp.com?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=discover_isembyld_hcp_0297" target="_blank" width="150" style="width:150px;display:inline-block;background-color:#12A166;padding-left:0;padding-right: 0;padding-bottom:8px;padding-top:8px;font-family:Arial,Helvetica,sans-serif;font-size:12px;line-height:16px;font-weight:700;color:#00205B;text-decoration:none">Discover ISEMBYLD</a> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td valign="middle" align="center" heigth="16" style="height:16px;line-height:16px;"> </td></tr></tbody></table></div> <!--[if (gte mso 9)|(IE)]> </td><td width="120" valign="top"> <![endif]--><div style="display:inline-block;width:100%;max-width:120px;vertical-align:top;"> <table border="0" cellpadding="0" cellspacing="0" width="110" role="none"><tbody><tr><td valign="middle" align="center" width="110" style="width:110px;border:2px solid #00205b;height:32px;background-color:#12A166;text-align:center;color:#00205B"> <a href="https://www.scholarrocksupports.com/hcp?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=now_approved_enroll_patient" target="_blank" width="110" style="width:110px;display:inline-block;background-color:#12A166; padding-left:0;padding-right:0;padding-bottom:8px;padding-top:8px;font-family:Arial,Helvetica,sans-serif;font-size:12px;line-height:16px;font-weight:700;color:#00205B;text-decoration:none">Enroll Patient</a> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td valign="middle" align="center" heigth="24" style="height:16px;line-height:16px;"> </td></tr></tbody></table></div> <!--[if (gte mso 9)|(IE)]> </td></tr></table> <![endif]--> </td></tr></tbody></table><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Sincerely] [Best] [Regards]<span style="color:#000000">,</span></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock field team member first name and last name] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock field team member title] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock field team member phone number] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock field team member email address] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:32px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#00205B"> In accordance with applicable state law, pricing information for ISEMBYLD (apitegromab-mstn) is available <a href="https://scholarrock.com/state-regulations-disclosures/" target="_blank" style="color:#00205B;text-decoration:underline">here</a>. </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:12px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:10px;line-height:12px;font-weight:400;color:#00205B"> <b>References:</b></div><div style="box-sizing:border-box;display:block;margin:0; margin-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:10px;line-height:12px;font-weight:400;color:#00205B"> <b>1.</b> ISEMBYLD. Prescribing information. Scholar Rock, Inc; 2026. <b>2.</b> Wirth B, Mendoza-Ferreira N, Torres-Benito L. Spinal muscular atrophy disease modifiers. In: Sumner CJ, Paushkin S, Ko CP, eds. <i>Spinal Muscular Atrophy: Disease Mechanisms and Therapy</i>. Elsevier; 2017:191-210. <b>3.</b> Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. <i>Neuromuscul Disord</i>. 2018;28(3):197-207. <b>4.</b> Servais L, Day JW, Deconinck N, et al. SUNFISH parts 1 and 2: 5-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). Poster presented at: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 16-19, 2025. Dallas, TX. <b>5.</b> Wu J, Pepler L, Maturi B, et al. Systematic review of motor function scales and patient-reported outcomes in spinal muscular atrophy. <i>Am J Phys Med Rehabil</i>. 2022;101:590-608. </div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;background-color:#00205B;padding-bottom:24px;padding-left:24px;padding-right:24px;padding-top:24px"><div style="box-sizing:border-box;text-align:left;display:block;margin:0 auto;margin-bottom:12px;"> <a href="https://scholarrock.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=scholar_rock_logo_0297" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-now-approved-email/footer-logo-scholar-rock.png" width="194" height="48" border="0" alt="" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic;display:inline-block"></a></div><div style="box-sizing:border-box;text-align:left;display:block; margin:0;margin-bottom:20px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <a href="https://scholarrock.com/contact-us/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=contact_us_footer_0297" target="_blank" style="color:#ffffff;text-decoration:none;">Contact Us</a> <a href="https://scholarrock.com/privacy-policy/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=privacy_policy_footer_0297" target="_blank" style="color:#ffffff;text-decoration:none;">Privacy Policy</a></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">301 Binney Street, 3rd Floor<br> Cambridge, MA 02142</span></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">ISEMBYLD is a trademark of Scholar Rock.<br> Scholar Rock © 2026. All rights reserved.<br> US-APIT-0297 09/26</span></div><div style="box-sizing: border-box;text-align:left;display:block;margin:0;margin-bottom:0;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> This advertisement is intended only for healthcare professionals in the United States.<br> Reply with “unsubscribe” to be removed from future ISEMBYLD Marketing communications. </div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table></center> </body></html>